| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441780 | European Journal of Cancer | 2015 | 7 Pages |
Abstract
The primary end-point was not met; low-dose erlotinib is not recommended for fit patients with NSCLC harbouring EGFR mutations. However, it may merit further evaluation for elderly or frail patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Kazuhiko Yamada, Hiromi Aono, Yukio Hosomi, Hiroaki Okamoto, Terufumi Kato, Yuko Komase, Masanori Nishikawa, Koichi Azuma, Hiroaki Takeoka, Yusuke Okuma, Yoshiro Nakahara, Akira Sato, Mari S. Oba, Satoshi Morita, Hideo Kunitoh, Koshiro Watanabe,